Carbohydrate-controlled serine protease inhibitor (serpin) production in Bifidobacterium longum subsp. longum

Duboux, Stéphane; Golliard, Mireille; Muller, Jeroen; Bergonzelli, Gabriela; Bolten, Christoph J.; Mercenier, Annick; Kleerebezem, Michiel

doi:10.1038/s41598-021-86740-y

Cited by 18 publications

(19 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary endpoints considered were assessments of symptom severity with IBS-SSS, an improvement of IBS symptoms using the global improvement scale (IBS-GIS), and adequate relief of symptoms after four and eight weeks of therapy. An earlier study found that increasing doses of scFOS were associated with an increase in concentrations of fecal bifidobacteria [ 97 ], which have beneficial effects on colonic pH regulation, favorable immune modulation, pathogen exclusion, increasing SCFA production, and anti-protease production [ 98 ]. In general, the consumption of synbiotics by IBS patients has been associated with improvements in overall IBS/health-related quality of life (outcomes: frequency and severity of pain, bloating severity, bowel movement frequency, and satisfaction).…”

Section: Intestinal Epithelial Barrier Disordersmentioning

confidence: 99%

Bioactive Compounds in Food as a Current Therapeutic Approach to Maintain a Healthy Intestinal Epithelium

et al. 2021

View full text Add to dashboard Cite

The intestinal epithelium serves as an effective barrier against the external environment, hampering the passage of potentially harmful substances (such as pathogenic microbes) that could trigger an exacerbated host immune response. The integrity of this barrier is thus essential for the maintenance of proper intestinal homeostasis and efficient protective reactions against chemical and microbial challenges. The principal consequence of intestinal barrier defects is an increase in intestinal permeability, which leads to an increased influx of luminal stressors, such as pathogens, toxins, and allergens, which in turn trigger inflammation and immune response. The fine and fragile balance of intestinal homeostasis can be altered by multiple factors that regulate barrier function, many of which are poorly understood. This review will address the role of gut microbiota as well as food supplements (such as probiotics, prebiotics, and synbiotics) in modulating gut health and regulating intestinal barrier function. In particular, we will focus on three human pathologies: inflammatory bowel disease, irritable bowel syndrome, and food allergy.

show abstract

Section: Intestinal Epithelial Barrier Disordersmentioning

confidence: 99%

Bioactive Compounds in Food as a Current Therapeutic Approach to Maintain a Healthy Intestinal Epithelium

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Bifidobacteria are natural inhabitants of the human gut and are known to display immunomodulatory properties. Members of this genus revealed a large repertoire of genes enabling their adaptation and resistance to the hostile GIT environment [ 134 , 135 , 136 ]. Among them, serpins are described to be involved in this interaction.…”

Section: Serpins Natural Inhibitors To Control the Activity Of Serine Proteasesmentioning

confidence: 99%

“…Nevertheless, sequencing of the genomes of more bifidobacterial species, together with recent advances made by metagenomic analysis, allowed the identification of several additional Bifidobacterial species-encoding serpins [ 121 , 137 ]. Intriguingly, induced transcription of Bifidobacterial serpins in response to different environmental conditions in the GIT has been highlighted [ 134 , 135 ]. This includes the presence of several prokaryotic and eukaryotic proteases [ 135 , 138 ].…”

Section: Serpins Natural Inhibitors To Control the Activity Of Serine Proteasesmentioning

confidence: 99%

Gut Serpinome: Emerging Evidence in IBD

Mkaouar

Mariaule

Rhimi

et al. 2021

IJMS

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) are incurable disorders whose prevalence and global socioeconomic impact are increasing. While the role of host genetics and immunity is well documented, that of gut microbiota dysbiosis is increasingly being studied. However, the molecular basis of the dialogue between the gut microbiota and the host remains poorly understood. Increased activity of serine proteases is demonstrated in IBD patients and may contribute to the onset and the maintenance of the disease. The intestinal proteolytic balance is the result of an equilibrium between the proteases and their corresponding inhibitors. Interestingly, the serine protease inhibitors (serpins) encoded by the host are well reported; in contrast, those from the gut microbiota remain poorly studied. In this review, we provide a concise analysis of the roles of serine protease in IBD physiopathology and we focus on the serpins from the gut microbiota (gut serpinome) and their relevance as a promising therapeutic approach.

show abstract

“…This notion is further confirmed by our recent study that demonstrated that in B. longum subsp. longum, serpin production is regulated by the carbohydrate-substrates used for growth, revealing galactose and fructose (or galacto-or fructo-di/oligo-saccharides) as inducing substrates, while the presence of glucose repressed serpin production almost completely (Duboux et al, 2021). These studies illustrate the diverse environmental factors and regulatory mechanisms involved in controlling serpin production in Bifidobacterium (sub-) species, indicating that growth conditions (e.g., substrate) could be tailored to ensure, or even enhance the production and function of this NF and/or EM in the final probiotic preparation.…”

Section: Environmental Factors Regulating Serine Protease Inhibitor Productionmentioning

confidence: 99%

The Possible Link Between Manufacturing and Probiotic Efficacy; a Molecular Point of View on Bifidobacterium

2021

View full text Add to dashboard Cite

Probiotics for food or supplement use have been studied in numerous clinical trials, addressing a broad variety of diseases, and conditions. However, discrepancies were observed in the clinical outcomes stemming from the use of lactobacillaceae and bifidobacteria strains. These differences are often attributed to variations in the clinical trial protocol like trial design, included target population, probiotic dosage, or outcome parameters measured. However, a contribution of the methods used to produce the live bioactive ingredients should not be neglected as a possible additional factor in the observed clinical outcome variations. It is well established that manufacturing conditions play a role in determining the survival and viability of probiotics, but much less is known about their influence on the probiotic molecular composition and functionality. In this review, we briefly summarize the evidence obtained for Lacticaseibacillus rhamnosus GG and Lactiplantibacillus plantarum WCFS1, highlighting that expression and presence of probiotic niche factor (NF) and/or effector molecules (EM) may be altered during production of those two well-characterized lactobacillaceae probiotic strains. Subsequently, we summarize in more depth what is the present state of knowledge about bifidobacterial probiotic NF and EM; how their expression may be modified by manufacturing related environmental factors and how that may affect their biological activity in the host. This review highlights the importance of gathering knowledge on probiotic NF and EM, to validate them as surrogate markers of probiotic functionality. We further propose that monitoring of validated NF and/or EM during production and/or in the final preparation could complement viable count assessments that are currently applied in industry. Overall, we suggest that implementation of molecular level quality controls (i.e., based on validated NF and EM), could provide mode of action based in vitro tests contributing to better control the health-promoting reliability of probiotic products.

show abstract

Carbohydrate-controlled serine protease inhibitor (serpin) production in Bifidobacterium longum subsp. longum

Cited by 18 publications

References 38 publications

Bioactive Compounds in Food as a Current Therapeutic Approach to Maintain a Healthy Intestinal Epithelium

Bioactive Compounds in Food as a Current Therapeutic Approach to Maintain a Healthy Intestinal Epithelium

Gut Serpinome: Emerging Evidence in IBD

The Possible Link Between Manufacturing and Probiotic Efficacy; a Molecular Point of View on Bifidobacterium

Contact Info

Product

Resources

About